| Course | NR 508 Advanced Pharmacology |
|---|---|
| Week | 3 |
| Paper type | Drug class analysis |
| Length | About 1,140 words, 4 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NR 508 Week 3
Calcium Channel Blockers as a Class: One Channel, an Axis Running From Arteriole to Atrioventricular Node, Ankle Edema That Rises From 1.8% to 10.8% With the Amlodipine Dose, and Nimodipine Held Back
Student Name
College of Nursing, Chamberlain University
NR 508: Advanced Pharmacology
Instructor Name
Month Day, Year
Calcium Channel Blockers as a Class: One Channel, an Axis Running From Arteriole to Atrioventricular Node, Ankle Edema That Rises From 1.8% to 10.8% With the Amlodipine Dose, and Nimodipine Held Back
The Action, Stated Once
Every calcium channel blocker in clinical use for cardiovascular disease blocks the L-type voltage-gated calcium channel. In vascular smooth muscle, calcium entering through this channel triggers contraction, so blocking it relaxes arterioles and lowers vascular resistance. In the heart, the same channel carries the calcium current that drives contraction in myocytes and the depolarization of cells in the sinoatrial and atrioventricular nodes, so blocking it there reduces contractility, slows the heart rate and slows conduction through the atrioventricular node.
Every predictable effect of the class, wanted and unwanted, descends from that one action applied to different tissues. That is why the rest of this analysis is organized by where the drugs act, not by listing them.
The Axis Members Vary Along
The members of the class differ mainly in how much of their effect falls on vessels and how much on the heart. At one end sit the dihydropyridines, such as amlodipine, nifedipine and felodipine, which act predominantly on vascular smooth muscle. At therapeutic doses they lower blood pressure by dilating arterioles and have little direct effect on the heart. The amlodipine prescribing information states that it has not been associated with a negative inotropic effect in the therapeutic dose range, even with beta-blockers, and does not change sinoatrial node function or atrioventricular conduction (Viatris Specialty, 2025).
At the other end sits verapamil, a phenylalkylamine, which acts strongly on the heart. Its label describes a negative inotropic effect that in most patients is offset by its reduction of afterload, but warns that in patients with severe left ventricular dysfunction it can worsen heart failure; in its clinical experience, 1.8% of 4,954 patients developed heart failure or pulmonary edema (A-S Medication Solutions, 2026). Diltiazem, a benzothiazepine, sits between them.
This axis predicts how a new member will behave. A newly approved dihydropyridine can be expected to lower blood pressure without slowing the heart, and to cause the vascular side effects of the class, before anyone has read its trials.
Class Effect or One Molecule
Some effects belong to the whole class, some to one end of the axis, and some to a single molecule, and mixing these levels produces wrong advice.
Peripheral edema belongs to the vascular end. Dihydropyridines dilate arterioles more than veins, so pressure in the capillaries of the legs rises and fluid leaks into the tissues. It is not caused by salt and water retention, which is why diuretics help it little. Verapamil causes edema far less often; its label lists edema at 1.9% (A-S Medication Solutions, 2026).
Constipation belongs to one molecule. Verapamil's label lists constipation at 7.3% of 4,954 patients, the most common reaction reported (A-S Medication Solutions, 2026). It reflects verapamil's action on calcium channels in the smooth muscle of the gut, which it blocks more than the dihydropyridines do. It should not be written up as a class effect, and a patient who was constipated on verapamil can reasonably be expected to do better on amlodipine.
Slowing the heart belongs to the cardiac end. Bradycardia and atrioventricular block are effects of verapamil and diltiazem, not of amlodipine, and this is why the two non-dihydropyridines are used to control the ventricular rate in atrial fibrillation while the dihydropyridines are not.
Interactions sit at the level of metabolism, which varies by member. Most members of the class are cleared by the liver enzyme CYP3A4, but verapamil and diltiazem also inhibit that enzyme, which the dihydropyridines do much less. A patient taking a statin or another CYP3A4-cleared drug is therefore more exposed to an interaction when verapamil or diltiazem is added than when amlodipine is. Here again the axis is useful: the members that act most on the heart are also the ones most likely to raise levels of other drugs.
Selectivity Has a Dose
The vascular selectivity of the dihydropyridines is real, but it is a matter of degree, and dose moves it. Amlodipine's own trials show edema rising with dose: 1.8% at 2.5 mg, 3.0% at 5 mg and 10.8% at 10 mg, against 0.6% on placebo. Flushing and palpitations rise with dose in the same way. Edema was also more common in women than in men, 14.6% against 5.6% in controlled trials (Viatris Specialty, 2025). A patient doubling from 5 to 10 mg is more than tripling the chance of swollen ankles, which is worth saying before the dose is raised.
Dose also exposed a hazard with one formulation. Short-acting nifedipine produces a rapid fall in blood pressure that triggers reflex sympathetic activation. A meta-analysis of 16 secondary prevention trials in coronary heart disease found that nifedipine was associated with increased total mortality, with a clear dose response: the risk ratio was 1.06 at 30 to 50 mg a day but 2.83 at 80 mg a day (Furberg et al., 1995). The finding concerns short-acting nifedipine at high doses in coronary disease, not the class and not long-acting dihydropyridines, and should not be generalized beyond that.
The Member Held Back
Nimodipine is a dihydropyridine that is not used for hypertension. Its labeled indication is to improve neurologic outcome by reducing the incidence and severity of ischemic deficits in adults with subarachnoid hemorrhage from a ruptured intracranial aneurysm (Azurity Pharmaceuticals, 2024). It sits at the vascular end of the axis but is used for a different purpose, which shows that the axis predicts where a drug acts but not every reason it is given. Treating nimodipine as simply another antihypertensive dihydropyridine would be a serious error, because lowering blood pressure too far in subarachnoid hemorrhage can reduce blood flow to a brain already at risk, and the drug is used there for its effect on the cerebral circulation, not on systemic pressure.
What the Analysis Lets a Prescriber Do
The class structure turns into choices. For a patient with hypertension and a heart rate already slow on a beta-blocker, a dihydropyridine is the member to choose, because it lowers pressure without adding to the slowing. For a patient with atrial fibrillation needing rate control, verapamil or diltiazem is the member, unless the ejection fraction is severely reduced. For a patient whose ankles swelled on amlodipine 10 mg, lowering the dose or switching ends of the axis addresses the mechanism, while adding a diuretic does not. And for a patient already constipated, verapamil is the member to avoid.
References
A-S Medication Solutions. (2026). Verapamil hydrochloride tablet, film coated, extended release [Prescribing information]. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed182ebe-8299-4680-9dea-ef79d30db683
Azurity Pharmaceuticals. (2024). Nymalize (nimodipine) solution [Prescribing information]. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e660fa26-b5c4-4d6d-8887-9e22b6666a10
Furberg, C. D., Psaty, B. M., & Meyer, J. V. (1995). Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation, 92(5), 1326-1331. https://doi.org/10.1161/01.CIR.92.5.1326
Viatris Specialty. (2025). Norvasc (amlodipine besylate) tablet [Prescribing information]. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7367289c-b0b0-466a-83e2-558e2985c29f
What the NR 508 Week 3 assignment asks for
The Week 3 analysis asks you to examine a drug class, its mechanism, its members and their differences. Plan on covering the shared mechanism, how members differ, class effects versus individual drug effects, dosing considerations, clinical implications and APA. State the shared action once and derive the expected effects from it. Find the single axis along which members differ. Place each effect at the right level: whole class, one end of the axis or one molecule. Show how dose changes selectivity, using label figures. Explain any member used for a different purpose. End with choices a prescriber can make from the structure.
How this NR 508 Week 3 example is built
The action section explains L-type channel blockade in vascular smooth muscle and the heart. The axis section places dihydropyridines at the vascular end and verapamil, a phenylalkylamine, at the cardiac end, with diltiazem between, and explains how the axis predicts a new member. The levels section explains dihydropyridine edema from arteriolar dilation, verapamil's constipation at 7.3% of 4,954 patients, bradycardia and block at the cardiac end and CYP3A4 interactions. The dose section shows amlodipine's edema rising with dose. The nifedipine section reports the dose-related mortality signal with the short-acting form. Nimodipine is explained as used to improve outcome after subarachnoid hemorrhage. The final section matches members to patients, such as a dihydropyridine for someone already slow on a beta-blocker. Each effect is cited to the label of the member it belongs to.
NR 508 Week 3 rubric: what full points look like
Drug class rubrics in NR 508 generally score an accurate mechanism, analysis of differences among members, correct placement of effects, dosing considerations, clinical application and APA. Placing effects at the right level is the row this analysis is built on, separating class, axis and molecule. The mechanism is credited for being stated once. Differences score through the single axis that predicts new members. Dosing earns points with the label's edema figures and the nifedipine example. Application is credited for patient-matched choices. Four prescribing labels and Furberg and colleagues support the paper. Explaining nimodipine by its tissue rather than as an exception shows the axis working.
Common NR 508 Week 3 mistakes, and how to avoid them
An analysis that collapses when a new member is added costs the most, because a class described only by listing its drugs predicts nothing. Another loss is calling every effect a class effect. Students also skip dose, ignore members used for other conditions or give advice that confuses vascular and cardiac agents. The newest agent belongs in the analysis if it fits the axis. Members used for different conditions should be explained by their place on the axis or their tissue. Keep pathophysiology to what explains the effects. Name your class and an NR 508 analysis can find the axis its members vary along. Test your axis on one member you have not discussed.
Get a NR 508 Week 3 example written to your instructions
Send the Week 3 instructions and the class your section assigned, plus the table if your classroom supplies one, and a custom example is written to them and returned inside 24 to 48 hours, the first one free. Say how many members the prompt expects and the example works at that scale rather than guessing at it.
More NR 508 papers and MSN samples
- NR 508 Week 1: Pharmacokinetic Property Post
- NR 508 Week 2: Dabigatran Pharmacokinetics Write-Up
- NR 508 Week 4: Case Application Paper
- NR 508 Week 5: Adverse Effect Analysis
- NR 508 Week 6: Therapeutic Failure Write-up
- NR 508 Week 7: Medication Teaching Plan
- NR 508 Week 8: Pharmacology Case Paper
- NR 510 Week 3: Practice Barrier Brief
- NR 506NP Week 3: Opposing Argument Analysis Paper
- NR 510F Week 3: Gap Analysis for the New NP Role
- NR 506 Week 3: Insulin Bill Legislative Process Paper
NR 508 Week 3 questions, answered
Does the newest agent in the class belong in the analysis?
It makes an excellent closing example precisely because it is unfamiliar. Bring it in at the end rather than in the body, and use it to show the prediction working: shared action gives you its likely profile, the axis of variation tells you which questions remain open. An analysis proving useful on a drug it never described is doing exactly what the course wants.
What if two members are used for entirely different conditions?
That is worth a paragraph rather than an apology. One action can be put to two purposes, and where members of a class have drifted into separate specialties the reason usually sits on the axis of variation: a difference in duration, in the tissue reached, or in the form available. Naming that reason is stronger analysis than treating the split as an oddity.
How much pathophysiology should the analysis carry?
One sentence of setup, no more. The subject here is the drug and the class it belongs to, so the disease appears only far enough to explain why anybody points this action at it. Write-ups that open with two pages on the condition arrive with the class analysis compressed into a final paragraph, and the rubric weights are almost never distributed that way.
Where can I find a free NR 508 Week 3 sample paper?
The complete Week 3 analysis of calcium channel blockers, with the shared action, the axis, effects at the right level, the role of dose, nimodipine, prescriber choices and five references, appears on this page.
How does amlodipine's dose affect edema in the NR 508 Week 3 analysis?
Ankle edema rises with dose, from about 1.8% at 2.5 mg to 10.8% at 10 mg in the label's trials, because arteriolar dilation raises capillary pressure in the legs.